In May of this year, the Ivoxidan anti injection developed by Kangfang Biotechnology for the treatment of lung cancer was approved for marketing. For many lung cancer patients, this domestically produced innovative drug has brought them new treatment opportunities. Previously, Kangfang Biotechnology also granted an exclusive license to a US innovative drug company for the development and commercialization of Ivosi in some overseas countries for up to $5 billion, allowing this Chinese innovative drug to go global. Kangfang Biotechnology is a locally cultivated biopharmaceutical research and development enterprise in the Guangdong Hong Kong Macao Greater Bay Area, which has developed over 50 innovative candidate drugs with independent intellectual property rights. The government departments in the Guangdong Hong Kong Macao Greater Bay Area are open-minded and efficient. Under policy guidance, they have built an innovative, dynamic, and internationally competitive industrial pattern, formed a synergistic and complementary industrial chain, gathered high-level and diversified talents, and built a good innovation industry ecology, driving the rapid formation of new quality productivity through innovation Founder and Chairman of Kangfang Biotechnology, Xia Yu, said. In Zhuhai, the Phase I clinical trial of the small molecule candidate drug NS-041 for the treatment of neurological and psychiatric disorders by Lizhu Pharmaceutical Group has been successfully completed and is about to enter the next stage of clinical development. We closely monitor cutting-edge tracks, innovative targets, and internationally leading stage products, constantly exploring new driving forces for innovative development, "said Yang Liang, Secretary of the Board of Directors of Lizhu Pharmaceutical Group. In recent years, the company has also continued to deeply cultivate the global pharmaceutical market and gradually move towards the top of the industrial value chain. In recent years, the Guangdong Hong Kong Macao Greater Bay Area has also emerged a number of innovative products, such as the domestic extracorporeal membrane oxygenation treatment system developed by Shenzhen Hannuo Medical Technology Co., Ltd., and the innovative drug Orebatinib independently developed by the Chinese Academy of Sciences Guangzhou Institute of Biomedicine and Health. According to data from the Guangdong Provincial Drug Administration, as of mid July this year, Guangdong Province has approved a total of 3 Class 1 innovative drugs, 1 new traditional Chinese medicine drug, 3 Class 2 innovative drugs, and 3 Class 3 innovative medical devices, with a total of 10 innovative drugs and devices approved, exceeding the total number for the whole year of 2023. From new drug research and development, production to clinical application, a virtuous cycle of the biopharmaceutical industry is accelerating within the Greater Bay Area, unleashing strong momentum. Since 2018, the annual compound growth rate of operating income of Guangdong's biopharmaceutical industrial enterprises has exceeded 10%; In 2023, the Guangdong Biomedical and Health Industry Cluster achieved a revenue of 663.8 billion yuan, ranking among the top in the country. The Guangdong Provincial Government released the "Action Plan for Further Promoting the High Quality Development of Guangdong's Biopharmaceutical Industry" in October this year, focusing on innovative mechanisms, improving products, clustering industries, and creating an environment. It puts forward 38 key tasks and measures, aiming to achieve a scale of over one trillion yuan in Guangdong's biopharmaceutical and health industry cluster and a scale of over 500 billion yuan in the pharmaceutical industry by 2027. The State Key Laboratory for Quality Research of Traditional Chinese Medicine (University of Macau) was established in 2010 with the approval of the Ministry of Science and Technology. For many years, the quality of traditional Chinese medicine has been the core scientific issue to promote the standardization, internationalization and modernization of traditional Chinese medicine. When entering the laboratory, it can be seen that containers such as Chinese medicine decocting pots and tamping jars are arranged together with drug delivery simulators, capsule filling machines and other equipment, and the cutting-edge technology of modern biomedicine is integrated with the essence of traditional Chinese medicine. The "Moderate Diversified Development Plan for the Macao Special Administrative Region Economy (2024-2028)" released by the Macao SAR Government in November 2023 clearly states that Macao should accelerate the development of the traditional Chinese medicine health industry, basically form the full chain development of traditional Chinese medicine industry university research, and gradually build a "national regional medical center". The Greater Bay Area is increasingly becoming a hot spot for the development of the biopharmaceutical industry, which cannot be separated from the collaborative innovation and complementary advantages of Guangdong, Hong Kong, and Macao. On November 9th, the first phase of the Guangdong Provincial Laboratory of Traditional Chinese Medicine was launched in the Hengqin Guangdong Macao Deep Cooperation Zone. The laboratory focuses on the four strategic needs of original theories of traditional Chinese medicine, prevention and treatment of major diseases, creation of new traditional Chinese medicine drugs, and international scientific and technological competition. It will carry out basic and applied research in five major fields, including the development of traditional Chinese medicine human immune defense and biosafety guarantee products, interpretation of traditional Chinese medicine syndrome differentiation and treatment and "disease syndrome combination" diagnosis and treatment principles, development of traditional Chinese medicine diagnosis and treatment plans for common major chronic diseases, development of modern traditional Chinese medicine diagnosis and treatment equipment, and creation of new traditional Chinese medicine drugs. The comprehensive strength of traditional Chinese medicine in Guangdong Province ranks among the top in the country, and the Zhuhai Special Economic Zone, combined with the Hengqin Guangdong Macao Deep Cooperation Zone, presents unparalleled institutional and geographical advantages Liu Liang, academician of the CAE Member and director of the Guangdong Provincial Laboratory of Traditional Chinese Medicine, said, "The laboratory will also integrate the superior resources of traditional Chinese medicine in Guangdong Province, Macao, Hong Kong and other places, carry out collaborative innovation, collaborative research, and promote collaborative development." (Li Xinshe)